Libero Pharma Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$1.06M
- Investors
-
2
Libero Pharma General Information
Description
Developer of a transdermal naltrexone patch designed to deliver naltrexone transdermally instead of a tablet or intramuscular injections. The company's transdermal patch mitigates the issue associated with existing formulations for use in the management of opiate addiction and alcohol use disorder and offers an alternative way of taking naltrexone, enabling doctors to treat patients with the disorder without any common naltrexone side effects.
Contact Information
Website
www.liberopharma.comCorporate Office
- International House
- 38 Thistle Street
- Edinburgh EH2 1EN
- Scotland, United Kingdom
Corporate Office
- International House
- 38 Thistle Street
- Edinburgh EH2 1EN
- Scotland, United Kingdom
Libero Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 01-Jan-2022 | $1.06M | Completed | Startup | ||
| 2. Early Stage VC | 10-May-2021 | Completed | Startup | |||
| 1. Early Stage VC | 29-Apr-2019 | $716K | $716K | Completed | Startup |
Libero Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 7,059 | $0.000133 | $45.24 | $45.24 | 1x | $45.24 | 2.61% | |
| Ordinary | 134,804 | $0.000133 | $5.43 | $5.43 | 1x | $5.43 | 49.8% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Libero Pharma Patents
Libero Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10729686-B2 | Pharmaceutical compositions | Active | 28-Feb-2008 | ||
| US-20170281562-A1 | Pharmaceutical compositions | Active | 28-Feb-2008 | ||
| US-20110064788-A1 | Pharmaceutical compositions for treatment of addiction | Active | 28-Feb-2008 | ||
| US-9700552-B2 | Pharmaceutical compositions for treatment of addiction | Active | 28-Feb-2008 | A61K31/485 |
Libero Pharma Signals
Libero Pharma Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| TRICAPITAL Angel Investors | Angel Group | Minority | ||
| Highland Venture Capital | Angel Group | Minority |
Libero Pharma FAQs
-
When was Libero Pharma founded?
Libero Pharma was founded in 2018.
-
Where is Libero Pharma headquartered?
Libero Pharma is headquartered in Edinburgh, United Kingdom.
-
What is the size of Libero Pharma?
Libero Pharma has 5 total employees.
-
What industry is Libero Pharma in?
Libero Pharma’s primary industry is Drug Discovery.
-
Is Libero Pharma a private or public company?
Libero Pharma is a Private company.
-
What is the current valuation of Libero Pharma?
The current valuation of Libero Pharma is .
-
What is Libero Pharma’s current revenue?
The current revenue for Libero Pharma is .
-
How much funding has Libero Pharma raised over time?
Libero Pharma has raised $3.08M.
-
Who are Libero Pharma’s investors?
TRICAPITAL Angel Investors and Highland Venture Capital have invested in Libero Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process